



France's Servier eyes €500 mn global sales from India drug tie-ups
Subscribe to enjoy similar stories. French drug innovator Servier is partnering with domestic players to develop, manufacture and export formulations for the global market, highlighting India’s growing role in global R&D.
The mid-sized pharmaceutical company said it aims to marry Indian expertise in chemical formulations and ‘incremental innovation’ with its discovery prowess to speed up drug development and manufacturing for its global markets. While Servier, the second largest French drugmaker, has been manufacturing locally in partnership with contract manufacturers for the Indian market, the company announced a €15 million investment to set up a platform called Gatinn to develop single-pill combinations for cardiometabolic and venous diseases in partnership with select contract development and manufacturing organisations (CDMOs), the company’s global leadership said at the launch of the platform on Tuesday.
The first product is expected to be shipped out by October 2027, and the drugmaker projects global sales of €500 million by 2030. Servier plans to export single-pill combinations or medicines that combine two or more active pharmaceutical ingredients (APIs)into a single pill to countries in regions such as Latin America, Asia, and Africa, where the burden of cardiometabolic diseases is high.
“In the context of single-pill combinations or incremental innovations, there are two dimensions. There is the molecule itself, and then how you put molecules together.
Read on livemint.com